RVV Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure

posted Jan 09, 2025 9:00am  by  Revive Therapeutics Ltd
Over the next few weeks data will be collected and analysed for effect size. Should the data show significant effects, Revive and the DRDC will discuss on the future development path. The results from this research study, if promising, will determine further studies to facilitate FDA and Health Canada approvals for the use of Bucillamine in nerve agents or organophosphate pesticide poisoning and explore its potential for traumatic brain injury caused by concussive or explosive forces and viral infections. ...read more